**ERCC6L**, a DNA helicase, is involved in cell proliferation and associated with survival and progress in breast and kidney cancers

Shao-Yan Pu1,2,*, Qin Yu1,2,3,*, Huan Wu1,2,3, Jian-Jun Jiang1,2,3, Xiao-Qiong Chen1,2, Yong-Han He1,2 and Qing-Peng Kong1,2

1State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, The Chinese Academy of Sciences, Kunming 650223, China
2KIZ/CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming 650223, China
3Kunming College of Life Science, University of Chinese Academy of Sciences, Beijing 100049, China

*These authors have contributed equally to this work

Correspondence to: Qing-Peng Kong, email: kongqp@mail.kiz.ac.cn
Yong-Han He, email: heyonghan@mail.kiz.ac.cn

Keywords: excision repair cross-complementation group 6 like, cancer, proliferation, MAPK

Received: July 02, 2016  Accepted: January 16, 2017  Published: February 02, 2017

Copyright: Pu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

By analyzing 4987 cancer transcriptomes from The Cancer Genome Atlas (TCGA), we identified that excision repair cross-complementation group 6 like (**ERCC6L**), a newly discovered DNA helicase, is highly expressed in 12 solid cancers. However, its role and mechanism in tumorigenesis are largely unknown. In this study, we found that **ERCC6L** silencing by small interfering RNA (siRNA) or short hairpin RNA (shRNA) significantly inhibited the proliferation of breast (MCF-7, MDA-MB-231) and kidney cancer cells (786-0). Furthermore, **ERCC6L** silencing induced cell cycle arrest at G0/G1 phase without affecting apoptosis. We then performed RNA sequencing (RNA-seq) analysis after **ERCC6L** silencing and identified that RAB31 was markedly downregulated at both the transcriptional and translational levels. Its downstream protein, phosphorylated MAPK and CDK2 were also inhibited by **ERCC6L** silencing. The xenograft experiment showed that silencing of **ERCC6L** strikingly inhibited tumor growth from the 7th day after xenograft in nude mice. In addition, higher **ERCC6L** expression was found to be significantly associated with worse clinical survival in breast and kidney cancers. In conclusion, our results suggest that **ERCC6L** may stimulates cancer cell proliferation by promoting cell cycle through a way of RAB31-MAPK-CDK2, and it could be a potential biomarker for cancer prognosis and target for cancer treatment.

INTRODUCTION

The rapid accumulation of cancer transcriptomic data provides a good opportunity for us to identify new cancer related genes and to deeply understand the molecular mechanism of the disease. We analyzed a total of 4987 transcriptomes of 12 cancer types from The Cancer Genome Atlas (TCGA) and found that excision repair cross-complementation group 6-like (**ERCC6L**) was highly expressed in almost all cancer types. **ERCC6L** is a newly discovered DNA helicase, also called **PICH** (Polo-like kinase 1-interacting checkpoint “helicase”). In 2005, Xu et al. first cloned **Ercc6l** from mouse embryos with an aim of looking for embryonic development related proteins [1]. Later, some studies reported that **ERCC6L** was overexpressed in embryonic heart, brain and other tissues [1]. Li et al. also showed that **ERCC6L** expression was significantly higher in the youngest deer than other age groups [2]. These studies indicate that **ERCC6L** is critical to embryonic development.

In 2007, Baumann et al. revealed that **ERCC6L** could combine with a mitosis regulation kinase (Polo-like kinase 1, **CDK1**). Later, several studies reported that **ERCC6L** could interact with MAPK pathways to regulate cell cycle progression [3]. This study aimed to further explore the role of **ERCC6L** in cancer cell proliferation and to identify the potential downstream targets of **ERCC6L**.
PLK1) and was involved in remodeling centromeric chromatin [3]. PLK1 plays wide roles in regulating cell division, cell proliferation and other biological processes, and is considered as a genetic marker in the development of tumors [4, 5]. The high expression of ERCC6L plus its role in embryonic development as well as the involvement of remodeling centromeric chromatin promote us to hypothesize that it may play a role in tumorigenesis. In fact, ERCC6L was showed to be required to affect mitotic centromere and chromosome structure in mammal cells [3, 6, 7]. For example, Hubner et al. found that the functional impairment of ERCC6L increased human embryonic kidney cell division by siRNA [8]. Rouzeau et al. also reported that ERCC6L can increase centromere division in the late fibroblast cell division [9]. However, the role of highly expressed ERCC6L in tumors has never been investigated.

In this study, we took breast and kidney cancers for examples and demonstrated for the first time that ERCC6L silencing inhibited the proliferation of cancer cells, and tumor growth in nude mice. We also reported significant associations of ERCC6L expression with clinical survival and progress in cancers. These results altogether suggest ERCC6L to be a new target for cancer treatment.

RESULTS

ERCC6L was significantly overexpressed in various cancers

We analyzed 4987 transcriptome of 12 cancer types from The Cancer Genome Atlas (TCGA) and found that ERCC6L was consistently overexpressed in all of the 12 cancers compared to their corresponding normal controls (all p<0.001, Figure 1). The results hint that abnormal expression of ERCC6L gene may play a role in tumorigenesis. As the sample size of breast and kidney cancers rank 1st and 2nd among the 12 cancer types (breast cancer: 1037 tumor vs. 110 normal tissues; kidney cancer: 518 tumor vs. 72 normal tissues) in TCGA, so we chose them as representatives to carry out the followed experiments.

ERCC6L silencing inhibited proliferation and induced cell cycle arrest

We knocked down ERCC6L by small interfering RNA (siRNA) (Supplementary Figure 1A) and found that ERCC6L silencing (si-ERCC6L) significantly inhibited the proliferation of MCF-7 cells in 24, 48, 72 and 97 h (p<0.05, Figure 2A). We then detected cell apoptosis using Annexin V in si-ERCC6L and si-Control cells, but did not observe any differences between the two groups (Figure 2B). Next we detected the effect of ERCC6L inhibition on cell cycle in MCF-7 cells and found that ERCC6L silencing induced cell cycle arrest at G0/G1 phase compared to the control group (Figure 2C and 2D). To verify the effect of ERCC6L on cell proliferation, we knocked down ERCC6L by shRNA (Supplementary Figure 1B) in another two cancer cell lines, a breast cancer cell line MDA-MB-231 and a kidney cancer cell line 786-0. The results showed that ERCC6L silencing by shRNA can also significantly inhibited the proliferation of MDA-MB-231 and 786-0 cells in 48, 72 and 96 h (p<0.05, Figure 2E and 2F). Similarly, ERCC6L silencing induced cell cycle arrest at G0/G1 phase compared to the control group in MDA-MB-231 and 786-0 cells (Figure 2G and 2H). These results indicate that the ERCC6L silencing was able to inhibit cell proliferation through inducing cell cycle arrest in multiple cancer cell lines.

ERCC6L silencing inhibited RAB31 and MAPK expression

To explore the mechanism of ERCC6L silencing in inhibiting cancer cell proliferation, we chose MCF-7 cell line to perform RNA-seq analysis after ERCC6L knockdown. We identified 77 significantly differentially expressed genes (DEGs) (e.g. MZT2B, NCKAP1, RAB31, FN1, HIPK3, PMP22, STC2, and ARPP19) between si-ERCC6L and si-Control groups (Figure 3A and Supplementary Table 1). Gene ontology (GO) analysis showed that the DEGs were mainly enriched in several important biological processes, such as cell death (p = 2.28E-05), death (p = 2.68E-05) and regulation of cytoskeleton organization (p = 9.20E-04) (Supplementary Figure 2). To confirm the RNA-seq result, we determined the mRNA levels of top 11 DEGs (MZT2B, NCKAP1, RAB31, FN1, HIPK3, PMP22, STC2, ARPP19, SLMO2, SSR1, and SERINC1) by quantitative real-time PCR (qRT-PCR). As a result, the MZT2B, NCKAP1, RAB31, FN1, HIPK3, PMP22, STC2, ARPP19 and SERINC1 were markedly downregulated after ERCC6L silencing (Figure 3B). Of them, RAB31, MZT2B, FN1, and ARPP19 have been reported to be associated with tumorigenesis (Supplementary Table 2) and were thus chosen for further protein validation. Finally, RAB31 and MZT2B were found to be downregulated by ERCC6L silencing at the translational level (Figure 3C), while the FN1 and ARPP19 were not changed. RAB31 was an upstream protein in the MAPK pathway and was involved in regulating cell proliferation [10]. ERCC6L silencing decreased the phosphorylation level of MAPK in breast cancer cells (Figure 3D and Supplementary Figure 3). CDK2 and Cyclin D1 (CCND1) are two proteins in the regulation of cell cycle from G1 to S phase [11, 12], which are two downstream target proteins of MAPK. We found that ERCC6L silencing did not change CCND1 expressions no matter at the transcriptional or translational levels (Figure 3D and Supplementary Figure 4). However, ERCC6L silencing can reduce CDK2 protein expression (Figure 3D).
**ERCC6L silencing inhibited tumor growth in nude mice**

To verify the role of ERCC6L in in-vitro experiment, we chose the invasive breast cancer cell line (MDA-MB-231) to perform xenograft tumor experiment in nude mice. The result showed that knockdown of ERCC6L strikingly suppressed the xenograft growth after 7 days of xenograft (Figure 4A-4C). However, body weight of mice was not significantly affected (Supplementary Figure 5).

**Figure 1:** ERCC6L expression in 12 cancer types from The Cancer Genome Atlas (TCGA). All p values are less than 4.5E-11 except for KICH (p = 0.0003).
Associations of clinical survival with \textit{ERCC6L} expression in breast and kidney cancer tumors

Since \textit{ERCC6L} knockdown can inhibit cancer cell proliferation \textit{in vitro} and tumor growth \textit{in vivo}, we wonder whether it was associated with clinical survivals. As shown in Figure 4D and 4E, both kidney and breast cancer patients with a higher expression level of \textit{ERCC6L} showed worse outcomes. We further analyzed the association of \textit{ERCC6L} expression with survival rates at different stages in breast and kidney cancers. \textit{ERCC6L} was obviously overexpressed in patients at stage II and III phase compared to those at stage I in breast cancer (Figure 4F). Moreover, high expression of \textit{ERCC6L} showed gradually worse outcome in breast cancer (Figure 4G-4I), showing significant difference at stage IV in breast cancer.

Figure 2: Effect of \textit{ERCC6L} knockdown on cell proliferation, apoptosis and cell cycle. A. Effect of \textit{ERCC6L} knockdown on cell proliferation at different time points in MCF-7 cells. B. Effect of \textit{ERCC6L} knockdown on cell apoptosis in MCF-7 cells. MCF7 cells were stained with Annexin V. C-D. Effect of \textit{ERCC6L} knockdown on cell cycle in MCF-7 cells. Effect of \textit{ERCC6L} knockdown on cell cycle significantly arrested at G0/G1 phase compared with the control in MCF-7 cells. The vertical axis shows the percentage of cells at different phases of cell cycle. E. Effect of \textit{ERCC6L} knockdown on cell proliferation at different time points in MDA-MB-231 cell lines. F. Effect of \textit{ERCC6L} knockdown on cell proliferation at different time points in 786-0 cells. G. Effect of \textit{ERCC6L} knockdown on cell cycle in MDA-MB-231 cells. H. Effect of \textit{ERCC6L} knockdown on cell cycle in 786-0 cells. \textit{ERCC6L} were silenced by siRNA in MCF-7 cells, and were silenced by two different shRNAs (sh#1-\textit{ERCC6L} and sh#2-\textit{ERCC6L}) in both MDA-MB-231 and 786-0 cell lines. Error bars represent mean ± SD. *p<0.05 compared to the control group. **p<0.01 compared to the control group. ***p<0.001 compared to the control group.
(Figure 4I) and in kidney cancer (Supplementary Figure 6), suggesting that the high expression of ERCC6L is an effective prognostic biomarker in cancers, at least in breast and kidney cancers.

DISCUSSION

In this study, we found that ERCC6L gene was consistently overexpressed in 12 solid tumors. It has been reported that ERCC6L combines with mitosis regulation kinase PLK1 and responds to remodel centromeric chromatin. As a coactor of ERCC6L, PLK1 has been well known as a genetic marker of tumor cell proliferation [13–15]. What is known about ERCC6L is its role in maintaining cell chromosome instability [6] and embryonic development [8], suggesting that ERCC6L might be a potential oncogene. Here we report for the first time that ERCC6L knockdown significantly inhibited cell proliferation in vitro and supressed tumor growth in vivo, and its high expression is significantly associated with bad outcome and progress in cancers, at least in breast and kidney cancers.

Cell cycle and apoptosis are two main performance in cancer cells [16]. We showed that apoptosis was not changed by ERCC6L knockdown, but cell cycle was significantly arrested at G0/G1 phase. These effects were validated in two breast and one kidney cancer cell lines. Cell cycle arrest is activated by DNA damage and/or malfunction of other critical organelles or structures (e.g. faulty mitotic spindle), which may cause apoptotic cascade [17]. However, it seems that the cell cycle arrest induced by ERCC6L knockdown was not enough to trigger cell apoptosis. This was supported by the unchanged protein expression of Cyclin D1 (CCND1), a key protein linked cell cycle to apoptosis [18]. Nevertheless, we can not exclude the possibility that ERCC6L silencing may induce other types of cell death, e.g. autophagy.

Figure 3: RNA-seq analysis after ERCC6L knockdown. A. Heatmap of genes with differential expression in MCF-7 cells after transfection. B. Validation of differentially expressed genes (DEGs) by qRT-PCR. β-actin was used as the internal control. C. Validation of reported cancer-associated DEGs (RAB31, MZT2B, FN1, and ARPP19) by western blot. β-actin was used as the internal control. D. Mitogen-activated protein kinase (MAPK), cyclin dependent kinase 2 (CDK2) and cyclin D1 (CCND1) protein levels after ERCC6L knockdown in MCF-7 cells. *p<0.05 compared to the si-control group. **p<0.01 compared to the si-control group. ***p<0.001 compared to the control group.
Our RNA-seq analysis identified the RAB31 as a candidate target of ERCC6L as it was the most downregulated gene at both the transcriptional and translational levels after ERCC6L silencing. Interestingly, RAB31 gene is member of the Ras superfamily, which can promote cell proliferation and migration in breast cancer cells [19]. Moreover, RAB31 has been reported to be an upstream regulator for MAPK [10]. ERK has been proved to be the best characterized MAPK and is considered to be a major regulator for cell growth and proliferation [20–23]. We found that the phosphorylated MAPK level was significantly suppressed by ERCC6L gene silencing, suggesting MAPK to be a likely downstream target of ERCC6L. Further, CDK2 and CCND1 are two proteins in the regulation of cell cycle from G1 to S phase [11, 12], acting as the downstream proteins of ERK [24, 25]. Although CCND1 expression was not changed by ERCC6L silencing in this study, CDK2 was markedly inhibited by ERCC6L knockdown (Figure 3D). These findings reveal that ERCC6L may reduce MAPK and CDK2 expressions through downregulating RAB31, thereby inhibiting cancer cell proliferation. These effects

Figure 4: Effect of ERCC6L silencing on tumor growth and associations of ERCC6L expression with clinical survival and progress of breast and kidney cancer. A. Tumor masses were harvested from MDA-MB-231-sh-Control and MDA-MB-231-sh#2 ERCC6L after tumors had grown for one month. B. Tumor weight after knockdown of ERCC6L. C. Changes in tumor volume after knockdown of ERCC6L in nude mice. D. Kaplan-Meier survival analysis in KIRC from TCGA. E. Kaplan-Meier survival analysis in BRCA from TCGA. F. Expression of ERCC6L at stage I, stage II, and stage III in breast cancer. G. Association of ERCC6L expression with survival at stage I in breast cancer. H. Association of ERCC6L expression with survival at stage II in breast cancer. I. Association of ERCC6L expression with survival at stage III in breast cancer. The clinical samples were divided into two groups according ERCC6L mRNA expression levels. High expression indicates that the mRNA value is greater than the median value of all tumors samples; Low expression indicates that the mRNA value is lower than the median value of all tumors samples. *p<0.05 compared to the sh-control group. **p<0.01 compared to the sh-control group. ***p<0.001 compared to the sh-control group.
of ERCC6L in vitro were validated by its inhibitory role in tumor growth in vivo, the latter exerts more obvious effect than the former.

The survival rate is an important indicator of clinical prognosis. We observed that the ERCC6L mRNA increased along with the progress of breast cancer and associated with poor overall survival, at least in breast and kidney cancers, suggesting it to be an effective marker for cancer progression.

In conclusion, in this study, we report for the first time that ERCC6L may stimulates cancer cell proliferation and promotes tumor growth. Because ERCC6L is consistently and highly expressed in most solid cancers, our findings imply that it could be a good potential biomarker and provide new insight into the role of ERCC6L in oncogenesis of solid tumors.

MATERIALS AND METHODS

Data acquisition

Gene expression data of 4987 samples (4415 tumors and 572 matched non-cancerous tissues) from 12 cancer types (Supplementary Table 3), and clinical data for breast and kidney cancers were downloaded from The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov, RNA-Seq Version 2). In our study, the gene expression data sets (level 3) have been processed by a slight normalization method in which the values of each individual sample were divided by 75 percentile to compare gene expression levels among samples in TCGA.

Cell culture and siRNA/shRNA transfection

Cell lines (MCF-7, MDA-MB-231 and 786-0) were bought from Conservation Genetics CAS Kunming Cell Bank and MCF-7 cells were cultured in DMEM/HIGH Glucose (HyClone, Logan, UT, USA), MDA-MB-231 were maintained in DMEM/F-12 (HyClone, Logan, UT, USA), 786-0 were cultured in RPMI medium (HyClone, Logan, UT, USA), supplemented with 10% fetal bovine serum (FBS) (Corning, Corning, NY, USA) and 1% penicillin/streptomycin (Gibco, Grand Island, NY, USA). MCF-7 cells were transfected with si-ERCC6L (target sequence: 5’-ACAAGATCTCTCCAGTATAAA-3’; sh#2, target sequence: 5’-CTTGCTAAAGACCGCATGATGACCT-3’) were constructed using pLKO.1 vector. Supernatants containing different lenti-viruses generated from HEK-293T cells were collected. Then MDA-MB-231 and 786-0 cells were infected by lentiviruses and selected using puromycin for 3 passages. Quantitative real-time PCR (qRT-PCR) was used to determine the effectiveness of the siRNA and shRNA knockdown.

Proliferation assay

MCF-7 cells were seeded at a density of 3 × 10^4 cells in 96-well plates. After 12 h, MCF-7 cells were transfected with si-ERCC6L and si-Control. Cell viability was determined using CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) on each day according to the manufacturer’s protocol. After incubation for 3 h at 37 °C, the absorbance was measured at 490 nm on a plate reader (Synergy H1, BioTek, Winooski, VT, USA).

MDA-MB-231 and 786-0 cells were seeded at a density of 3 × 10^4 cells in 96-well plates. After 12 h, cell viability was also determined using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit according to the manufacturer’s protocol.

Quantitative RT-PCR (qRT-PCR)

Cells were collected at 48 h after transfection. Total RNA were extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed with random nucleotide primers using GoScript™ reverse transcription system according to the manufacture’s protocol (Promega, Madison, WI, USA). qRT-PCR with gene-specific primers was performed using GoTaq qPCR master mix (Promega, Madison, WI, USA). β-actin was used as the internal control. The expression of target genes was calculated by 2^(-ΔΔCT) method. The primers were shown in Supplementary Table 4.

Western blot

Cells were lysed with RIPA Lysis Buffer (Beyotime, Haimen, Jiangsu, China). Proteins were quantified by BCA Protein Assay Kit (Beyotime, Haimen, Jiangsu, China). 20-50 μg of total proteins were loaded onto SDS-PAGE and subsequently transferred to PVDF membranes (Bio-Rad, Richmond, CA, USA). Membranes were incubated with the following primary antibodies: anti-RAB31, anti-FN1, anti-MZT2B, anti-ARPP19, anti-ERK1/2 and anti-p-ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-β-actin (Beyotime, Haimen, Jiangsu, China). The detailed protocol was described in our previous study [26].
Apoptosis assay and cell cycle analysis

Cells were harvested at 48 h after transfection, apoptosis were determined using the Annexin V apoptosis detection kit (eBioscience, San Diego, CA, USA) according to manufacturer’s protocol. Cells were collected 48 h after transfection and fixed with cold 75% alcohol at 4 °C overnight. Alcohol was removed and cells were washed with cold phosphate buffer saline (PBS). Cells were stained with propidium iodide solution containing 20 μg/ml RNase and incubated at room temperature for 30 min. After filtration by a nylon mesh filter, cell cycle was performed on a fluorescence-activated cell sorting (FACS, FACSVerse) analysis. Data were analyzed using the Flowjo software (Version 7.6.1, Tree Star Software, San Carlos, CA, USA).

Tumorigenesis in nude mice

For the MDA-MB-231 xenograft tumor growth experiment, a total of 10 female BALB/c mice at 5 weeks of age (Vital River, Beijing) were randomly divided into 2 groups. MDA-MB-231-sh-Control and MDA-MB-231-sh#2 ERCC6L cells (4 × 10^6 cells/point subcutaneously) were injected into inguen at two sides of each mouse. Tumor sizes in two groups were measured twice per week for one month using vernier calipers once tumors became palpable. Tumor volume was calculated using the following equation: tumor volume (mm^3) = (length × width^2)/2. All mice were sacrificed at the end of the experiment and tumors were harvested and weighed.

RNA extraction and RNA sequencing

After ERCC6l silencing, total RNA was isolated using Trizol reagent according to the manufacturer’s instructions. Poly(A) mRNA was isolated using oligo (dT) beads from 1 μg of total RNA for each sample. The construction of RNA-seq library was based on TruSeqTM RNA library preparation protocol. RNA-seq was completed by Novogene company (Beijing, China). The raw data of RNA-seq were processed using CASAVA V1.6 package. The quality control of each sample was accomplished using FASTQC V2.1.2.10. Clean reads were used in the whole analysis process.

Gene mapping and gene annotation

The human genomic data hg 19 build and gene annotation information was downloaded from UCSC database (http://genome.ucsc.edu/). We mapped the clean reads onto human genome hg 19 build using the alignment software Bowtie2 (https://sourceforge.net/projects/bowtie-bio/files/bowtie2/2.2.5/). Then we obtained transcript quantification from RNA-Seq data and calculated gene expression level using RSEM V1.1.17 software (http://deweylab.github.io/RSEM/). To estimate the level of gene expression, the reads count was transformed into reads per kilo bases per million mapped reads (RPKM) which reflects the abundance of gene expression [27]. The values of each individual sample were divided by 75 percentile to compare gene expression levels among samples. We identified differentially expressed genes using NOISeq package [28]. The Generic Annotation File (GAF) that provides all of our annotations for genes was downloaded from TCGA database (https://tcga-data.nci.nih.gov/tcgafiles).

Gene set enrichment analysis

Gene ontology biological process and pathway were analyzed using the David database (https://david.ncifcrf.gov/). Gene list for biological process and pathway was got from GeneCards (http://www.genecards.org).

Statistical analysis

Statistical analyses were performed using R software (V 2.6) (http://www.R-project.org/). P values less than 0.05 were considered statistically significant. In RNA-seq analysis, probability of gene expression difference > 0.8 is considered differentially expressed.

ACKNOWLEDGMENTS

This work was supported by grants from the Chinese Academy of Sciences (KJZD-EW-L14 and QYZDB-SSW-SMC020), National Basic Research Program of China (2012CB518205), the National Natural Science Foundation of China (81272309, 31322029, 81500670 and 81671404), and grant from the Youth Innovation Promotion Association of Chinese Academy of Sciences (to Y.H.H).

CONFLICTS OF INTEREST

The authors declare no conflicting financial interests.

REFERENCES

1. Xu YJ, Chen XG, Li Y. Ercc6l, a gene of SNF2 family, may play a role in the teratogenic action of alcohol. Toxicol Lett. 2005; 157:233-239.
2. Yin Y, Tang L, Zhang J, Tang B, Li Z. Molecular cloning and gene expression analysis of Ercc6l in Sika deer (Cervus nippon hortulorum). PloS One. 2011; 6:e20929.
3. Baumann C, Korner R, Hofmann K, Nigg EA. PICH, a centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint. Cell. 2007; 128:101-114.
4. Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL.
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res. 2015; 75:405-414.

5. Helmke C, Becker S, Strebehardt K. The role of Plk3 in oncogenesis. Oncogene. 2016; 35:135-147.

6. Kurasawa Y, Yu-Lee LY. PICH and cotargeted Plk1 coordinately maintain prometaphase chromosome arm architecture. Mol Biol Cell. 2010; 21:1188-1199.

7. Leng M, Bessudo D, Jung SY, Wang Y, Qin J. Targeting Plk1 to chromosome arms and regulating chromosome compaction by the PICH ATPase. Cell Cycle. 2008; 7:1480-1489.

8. Hubner NC, Wang LHC, Kaulich M, Descombes P, Poser I, Nigg EA. Re-examination of siRNA specificity questions role of PICH and Tao1 in the spindle checkpoint and identifies Mad2 as a sensitive target for small RNAs. Chromosoma. 2010; 119:149-165.

9. Rouzeau S, Cordelieres FP, Buhagiar-Labarchede G, Hurbain I, Onclercq-Delic R, Gemble S, Magnaghi-Jaulin L, Jaulin C, Amor-Gueret M. Bloom’s syndrome and PICH helicases cooperate with topoisomerase II alpha in centromere disjunction before anaphase. PLoS One. 2012; 7:e33905.

10. Pan Y, Zhang Y, Chen L, Liu Y, Feng Y, Yan J. The critical role of Rab31 in cell proliferation and apoptosis in cancer progression. Mol Neurobiol. 2015; 7:4431-4437.

11. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009; 69:6565-6572.

12. Kleinberger-Doron N, Shelah N, Capone R, Gazit A, Levitzki A. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp Cell Res. 1998; 241:340-351.

13. Li J, Wang R, Schweickert PG, Karki A, Yang Y, Kong Y, Ahmad N, Konieczny SF, Liu X. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer. Mol Cell. 2016; 15:711-719.

14. Wierer M, Verde G, Pisano P, Molina H, Font-Mateu J, Di Croce L, Beato M. PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription. Cell Rep. 2013; 3:2021-2032.

15. Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, RatliffT, Liu X. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res. 2014; 74:6635-6647.

16. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411:342-348.

17. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007; 10:13-29.

18. Kranenburg O, vanderEb A, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. Embo J. 1996; 15:46-54.

19. Grismayer B, Solch S, Seubert B, Kirchner T, Schafer S, Baretton G, Schmitt M, Luther T, Kruger A, Kotzsch M, Magdolen V. Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells. Mol Cancer. 2012; 11:62.

20. L, Jaulin C, Amor-Gueret M. Bloom’s syndrome and PICH helicases cooperate with topoisomerase II alpha in centromere disjunction before anaphase. PLoS One. 2012; 7:e33905.

21. D’Souza WN, Chang CF, Fischer AM, Li M, Hedrick SM. The Erk2 MAPK regulates CD8 T cell proliferation and survival. J Immunol. 2008; 181:7617-7629.

22. Grassian AR, Metallo CM, Colloff JL, Stephanopoulos G, Brugge JS. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev. 2011; 25:1716-1733.

23. Zhang B, Gu Y. Low expression of ERK signaling pathway affecting proliferation, cell cycle arrest and apoptosis of human gastric HGC-27 cells line. Mol Biol Rep. 2014; 41:3659-3669.

24. Bokemeyer D, Panek D, Kitahara M, Trzaskos JM, Muller CE, Hockemeyer J, Kunter U, Boor P, Floege J, Kramer HJ, Ostendorf T. The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis. Nephrol Dial Transplant. 2007; 22:3431-3441.

25. Wang HY, Yang SL, Liang HF, Li CH. HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways. Int J Mol Sci. 2014; 15:3507-3518.

26. He Y, Li Y, Zhao T, Wang Y, Sun C. Ursolic acid inhibits adipogenesis in 3T3-L1 adipocytes through LKB1/AMPK pathway. PloS One. 2013; 8:e70135.

27. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5:621-628.

28. Tarazona S, Furio-Tari P, Turra D, Pietro AD, Nueda MJ, Ferrer A, Conesa A. Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. Nucleic Acids Res. 2015; 43:e140.